Contineum Therapeutics, Inc.
About Contineum Therapeutics, Inc.
Contineum Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the development of oral small-molecule therapies for neurological, inflammatory, and immunological conditions. The company focuses on developing selective compounds targeting challenging molecular pathways and has built a portfolio of small molecule drug candidates. Its pipeline includes drug candidates in clinical development, such as PIPE-791, an LPA1 receptor antagonist being studied for idiopathic pulmonary fibrosis and chronic pain, and PIPE-307, an M1 receptor inhibitor being evaluated for relapsing-remitting multiple sclerosis and other depressive disorders.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2024
- $0
- Net income
- -$60.0M
- Total assets
- $276.6M
- Market cap
- $429.6M
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $0
- Operating expenses
- $68.1M
- Operating income
- -$68.1M
- Income tax
- $0
- Net income
- -$60.0M
- EPS (basic)
- $-2.17
- EPS (diluted)
- $-2.17
Balance sheet
- Total assets
- $276.6M
- Current assets
- $267.9M
- Total liabilities
- $15.7M
- Current liabilities
- $9.7M
- Shareholders’ equity
- $261.0M
Cash flow
- Operating cash flow
- -$55.3M
- Investing cash flow
- -$3.7M
- Financing cash flow
- $112.7M
- Net cash flow
- $53.7M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $429.6M
- EPS (diluted)
- $-2.17
- Shares outstanding
- 37.3M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Apr 5, 2024
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $60.0M in FY2024.
- Trading 28% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Contineum Therapeutics, Inc..
Write a review
News about Contineum Therapeutics, Inc.
News & sentiment via Polygon.io
